Carcinogen in Zantac Leads to Another Shipment Halt, Recall - (Bloomberg via NewsPoints Desk)

  • Bloomberg reported that Dr. Reddy's Laboratories is suspending all distribution of its ranitidine products, the generic version of Sanofi's H2 blocker Zantac, as a precautionary measure.

  • The company plans "to provide an update in the coming days," said spokeswoman Lori McCreary.

  • The news follows a similar move by Novartis' Sandoz unit, which halted global distribution of its generic version of Zantac earlier this week.

  • Regulators in the US and Europe said recently that they were investigating the discovery of the probable human carcinogen N-nitrosodimethylamine, or NDMA, in branded and generic Zantac.

  • Separately, the Italian Drug Agency stated that it was ordering a recall of all versions of Zantac with active ingredient made by the India-based firm Saraca Laboratories.

  • Italian regulators also banned the use of some types of Zantac produced by other pharmaceutical companies pending analysis of the drugs.

To read more NewsPoints articles, click here.